Africa possesses one of the most valuable and underleveraged assets in the global knowledge economy: its genomic diversity. Yet despite this advantage, the majority of economic value derived from African biological data continues to be captured outside the continent.
According to research published by the National Institutes of Health, over 80% of genomic data used in global studies originates from populations of European descent. African populations, despite being the most genetically diverse in the world, remain significantly underrepresented. This imbalance is not just a scientific gap it is an economic one.
The question is no longer whether African genomic data is valuable. The question is: who profits from it?
Africa’s Genomic Advantage
Human genetic diversity is highest in African populations due to the continent’s role as the origin of modern humans. This diversity provides a unique dataset for understanding disease mechanisms, drug responses, and genetic mutations at a level not possible elsewhere.
For pharmaceutical companies and research institutions, this translates into a strategic advantage:
• More accurate identification of disease pathways
• Improved drug efficacy across diverse populations
• Faster development of targeted therapies
The global precision medicine market continues to expand, driven by advances in genomics and personalized treatment approaches. According to estimates from the World Bank, investments in health innovation are increasingly concentrated in data-intensive sectors such as biotechnology and AI-driven diagnostics.
Africa’s genomic dataset is therefore not just scientifically valuable it is commercially strategic.
The Economics of Extraction
Historically, the relationship between Africa and global biotech has mirrored patterns seen in other resource sectors. Biological samples are collected locally, often through research collaborations, and then exported for analysis in laboratories based in North America or Europe.
Once processed, the resulting intellectual property whether in the form of patents, therapies, or datasets is largely owned by foreign entities.
This creates a familiar economic structure:
• Raw data originates in Africa
• Processing occurs externally
• Value is captured outside the continent
The World Health Organization has highlighted the risks associated with this model, particularly in the context of equitable access to medical innovation. Countries that do not control research pipelines often face higher costs and delayed access to treatments derived from their own data.
In effect, Africa is participating in the biotech value chain but primarily at its lowest-margin segment.
Biotech Partnerships: Collaboration or Dependency?
Global biotech partnerships are often framed as mutually beneficial, providing African institutions with access to funding, technology, and expertise. While these benefits are real, they also introduce structural dependencies.
Key dynamics within these partnerships include:
• Foreign control of research infrastructure
• Intellectual property ownership concentrated abroad
• Limited local commercialization capacity
The African Development Bank has noted that research and development spending across the continent remains below 1% of GDP in most countries, compared to significantly higher levels in developed economies. This funding gap reinforces reliance on external partners.
As a result, even when African data is central to discovery, African institutions often play a secondary role in value capture.
The Emerging Data War
The concept of a “data war” has traditionally been associated with digital platforms and user information. However, biological data is rapidly becoming a parallel domain of strategic competition.
Genomic data differs from traditional digital data in one critical respect: it is finite and inherently tied to populations. Once collected and sequenced, it cannot be replicated in the same way as digital content.
This makes African genomic data uniquely valuable and contested.
Countries and companies that control this data can influence:
• Global research priorities
• Pharmaceutical development pipelines
• Pricing and access to future therapies
The stakes are therefore not only economic but geopolitical. Control over biological data is increasingly linked to national security, healthcare sovereignty, and long-term economic competitiveness.
Constraint Layer: Infrastructure and Policy Gaps
Despite its advantages, Africa faces significant barriers to retaining and monetizing genomic data. The African Development Bank has identified persistent gaps in research infrastructure, regulatory frameworks, and human capital as key constraints.
These challenges include:
• Limited genomic sequencing capacity
• Inadequate data storage and processing infrastructure
• Fragmented policies on data ownership and sharing
Without coordinated policy responses, individual countries risk negotiating partnerships from a position of weakness, further entrenching external control over valuable datasets.
From Resource Extraction to Data Sovereignty
The parallels between biological data and traditional resource extraction are increasingly difficult to ignore. Just as oil and minerals once defined economic relationships between Africa and the rest of the world, data both digital and biological is now shaping a new set of dynamics.
The difference is that genomic data offers a pathway to higher-value participation in the global economy, provided that ownership and processing capabilities are localized.
This requires a shift in strategy:
• Investment in local research infrastructure
• Development of regulatory frameworks for data protection
• Negotiation of equitable terms in global partnerships
Countries that succeed in this transition will not only improve healthcare outcomes but also capture a greater share of the economic value generated by their data.
Structural Outlook
Africa’s genomic diversity represents one of the most significant untapped datasets in the world. Yet its value will ultimately be determined not by its existence, but by who controls it.
The current trajectory suggests that without deliberate intervention, much of this value will continue to be externalized. However, the growing recognition of data sovereignty across both digital and biological domains indicates a shift in how governments and institutions are approaching the issue.
Biotechnology may still be an emerging sector in Africa, but its strategic importance is already clear. The next phase of global competition will not be limited to oil, minerals, or even digital platforms it will extend into the biological data that underpins future innovation.
In that context, African DNA is not just a scientific resource. It is an economic asset, a geopolitical lever, and potentially, the foundation of the continent’s next data-driven industry.
